These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24973012)

  • 21. The orphan nuclear receptor LRH-1 and ERα activate GREB1 expression to induce breast cancer cell proliferation.
    Chand AL; Wijayakumara DD; Knower KC; Herridge KA; Howard TL; Lazarus KA; Clyne CD
    PLoS One; 2012; 7(2):e31593. PubMed ID: 22359603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells.
    Li Z; Li Y; Han D; Wang X; Li C; Chen T; Li W; Liang Y; Luo D; Chen B; Wang L; Zhao W; Yang Q
    Cell Death Dis; 2023 Jul; 14(7):482. PubMed ID: 37524698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
    Laganière J; Deblois G; Giguère V
    Mol Endocrinol; 2005 Jun; 19(6):1584-92. PubMed ID: 15831516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells.
    Lo R; Burgoon L; Macpherson L; Ahmed S; Matthews J
    Biochim Biophys Acta; 2010; 1799(5-6):469-79. PubMed ID: 20079471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.
    Berger CE; Qian Y; Liu G; Chen H; Chen X
    J Biol Chem; 2012 Aug; 287(36):30117-27. PubMed ID: 22787161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
    Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z
    Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
    Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
    Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
    Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
    PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α.
    Dou XW; Liang YK; Lin HY; Wei XL; Zhang YQ; Bai JW; Chen CF; Chen M; Du CW; Li YC; Tian J; Man K; Zhang GJ
    Theranostics; 2017; 7(16):4041-4056. PubMed ID: 29109797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
    Ford CE; Ekström EJ; Andersson T
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.
    Groenendijk FH; Zwart W; Floore A; Akbari S; Bernards R
    Breast Cancer Res Treat; 2013 Aug; 140(3):475-84. PubMed ID: 23912957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor-α, RBCK1, and protein kinase C β 1 cooperate to regulate estrogen receptor-α gene expression.
    Gustafsson Sheppard N; Heldring N; Dahlman-Wright K
    J Mol Endocrinol; 2012 Dec; 49(3):277-87. PubMed ID: 23042805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MTA1 expression correlates significantly with ER-alpha methylation in breast cancer.
    Mao XY; Chen H; Wang H; Wei J; Liu C; Zheng HC; Yao F; Jin F
    Tumour Biol; 2012 Oct; 33(5):1565-72. PubMed ID: 22644675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.